SEC Stock Data Quick Answer AMERICAN ELECTRIC POWER CO INC reported Total Assets of $114.46 billion for fiscal year 2025. AMERICAN ELECTRIC POWER CO INC Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $114.46B +11.0% 2024 $103.08B +6.6% 2023 $96.68B +3.5% 2022 $93.40B +6.5% 2021 $87.67B +8.6% 2020 $80.76B +6.4% 2019 $75.89B +10.3% 2018 … Read more
Quick Answer AMERICAN ELECTRIC POWER CO INC reported Diluted EPS of $6.66 per share for fiscal year 2025. AMERICAN ELECTRIC POWER CO INC Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 $6.66 +19.4% 2024 $5.58 +31.6% 2023 $4.24 -5.6% 2022 $4.49 -9.5% 2021 $4.96 +12.2% 2020 $4.42 +13.9% 2019 $3.88 -0.5% … Read more
Quick Answer AMERICAN ELECTRIC POWER CO INC reported Net Income of $1.48 billion for fiscal year 2013. AMERICAN ELECTRIC POWER CO INC Net Income — Annual History Fiscal Year Net Income YoY Change 2013 $1.48B +17.6% 2012 $1.26B -35.3% 2011 $1.95B +60.3% 2010 $1.21B -10.7% 2009 $1.36B -1.7% 2008 $1.38B +26.6% 2007 $1.09B — Quarterly … Read more
Quick Answer AMERICAN ELECTRIC POWER CO INC reported Total Revenue of $21.88 billion for fiscal year 2025. AMERICAN ELECTRIC POWER CO INC Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $21.88B +10.9% 2024 $19.72B +3.9% 2023 $18.98B -3.3% 2022 $19.64B +17.0% 2021 $16.79B +12.6% 2020 $14.92B -4.1% 2019 $15.56B -3.9% 2018 … Read more
Quick Answer AMERICAN ELECTRIC POWER CO INC reported Total Revenue of $21.88 billion for fiscal year 2025. AMERICAN ELECTRIC POWER CO INC — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $21.88B+10.9% $19.72B+3.9% $18.98B-3.3% $19.64B+17.0% $16.79B+12.6% $14.92B-4.1% Net Income — — — — — — Diluted EPS $6.66+19.4% $5.58+31.6% $4.24-5.6% … Read more
Quick Answer AEON Biopharma, Inc. reported Shares Outstanding of 12.11 million shares for fiscal year 2025. AEON Biopharma, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 12.11M +2079.2% 2024 555,511 +7.6% 2023 516,404 -99.6% 2022 138.83M — Quarterly Shares Outstanding Quarter Ending Shares Outstanding YoY QoQ September 30, 2025 11.64M … Read more
Quick Answer AEON Biopharma, Inc. reported Operating Income of -$12.80 million for fiscal year 2025. AEON Biopharma, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$12.80M -117.5% 2024 $72.98M +250.7% 2022 -$48.43M -2401.6% 2021 -$1.94M -53856.0% 2020 -$3.6K — Quarterly Operating Income Quarter Ending Operating Income YoY QoQ September 30, … Read more
Quick Answer AEON Biopharma, Inc. reported R&D Expense of $4.09 million for fiscal year 2025. AEON Biopharma, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $4.09M -71.1% 2024 $14.18M -59.2% 2022 $34.75M — Quarterly R&D Expense Quarter Ending R&D Expense YoY QoQ September 30, 2025 $597.0K -38.6% -43.9% June 30, … Read more
Quick Answer AEON Biopharma, Inc. reported Stockholders Equity of -$55.03 million for fiscal year 2025. AEON Biopharma, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 -$55.03M -92.6% 2024 -$28.57M +81.3% 2023 -$153.04M -191.6% 2023 $167.14M +158.1% 2022 -$287.50M -1598.2% 2021 -$16.93M -79167.1% 2020 $21.4K — Quarterly Stockholders Equity Quarter Ending … Read more
Quick Answer AEON Biopharma, Inc. reported Cash and Equivalents of $3.01 million for fiscal year 2025. AEON Biopharma, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $3.01M +23023.1% 2024 $13.0K -99.7% 2023 $5.16M -83.5% 2023 $31.20M +220.1% 2022 $9.75M +1859.3% 2021 $497.4K — Quarterly Cash and Equivalents Quarter … Read more